Skip to main content
Clinical Trials/ISRCTN12125882
ISRCTN12125882CompletedNot Applicable

Influence of topical anti-VEGF (Ranibizumab) on the outcome of filtration surgery for glaucoma: A two phased study with a randomised placebo controlled trial

Horten Center, University of Zurich (Switzerland)0 sites50 target enrollmentStarted: August 18, 2010Last updated:

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
50

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Sex
All

Inclusion Criteria

  • 1. Patients with primary open angle glaucoma (POAG), PEX and pigment dispersion Glaucoma
  • 2. At least 18 years of age
  • 3. No previous intraocular surgery undergoing trabeculectomy or phaco-trabeculectomy

Exclusion Criteria

  • 1. Patients with primary angle closure glaucoma (PACG)
  • 2. Glaucoma due to other causes
  • 3. Previous intra- and extraocular surgery
  • 4. Any surgery during the last 3 months
  • 5. Patients with uveitis or inflammatory ocular surface disease
  • 6. Patients with single eyes
  • 7. Patients presenting the first postoperative day with bleb leak, hypotony or situations that potentially need another surgery
  • 8. Pregnant and breast feeding women
  • 9. Women planning to get pregnant

Investigators

Sponsor
Horten Center, University of Zurich (Switzerland)

Similar Trials

Completed
Not Applicable
The efficacy of topical NSAIDs for anti-VEGF therapy for vitreomacular diseaseretinal vein occlusion diabetic retinopathy age related macular degeneration
JPRN-UMIN000014929TT East japan Tohoku Hospital200
Completed
Not Applicable
Anti-VEGF (bevacizumab/ranibizumab) versus RPE-choroid graft in the treatment of 1) non-responders to 3 intravitreal anti-VEGF injections, or 2) patients with AMD and pigment epithelium rip, or 3) patients with AMD and massive haemorrhage. A randomized trial.Exudative age-related macular degeneration in combination with either 1) visual loss of ¡Ý 15 letters on the ETDRS chart after 3 anti-VEGF injections, 2) subfoveal RPE-tear, or 3) massive submacular haemorrhage.
NL-OMON29614Oogziekenhuis Rotterdam (OZR)240
Recruiting
Not Applicable
The effect of anti-VEGF treatments for neovascular,exudative and inflammatory ocular diseasesOcular diseases including neovascular, serous and inflammatory diseases
JPRN-UMIN000021589The department of ophthalmology,Tohoku university graduate School of Medicine3,000
Active, not recruiting
Phase 1
IMPACT OF ANTI-TNF, VEDOLIZUMAB AND TOFACITINIB ON AORTIC STIFFNESS, CAROTID INTIMA-MEDIA THICKNESS AND CARDIOVASCULAR RISK OF PATIENTS WITH ULCERATIVE COLITISulcerative colitis
EUCTR2020-004391-18-FRCHU Amiens-Picardie100
Completed
Phase 3
Anti-VEGF (bevacizumab/ranibizumab) versus RPE-choroid graft in the treatment of 1) non-responders to 3 intravitreal anti-VEGF injections, or 2) patients with AMD and pigment epithelium rip, or 3) patients with AMD and massive haemorrhage. A randomized trial.age-relatede macular degeneration10047060
NL-OMON33994Oogziekenhuis Rotterdam40